Teacher Retirement System of Texas bought a new position in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) in the 4th quarter, Holdings Channel reports. The institutional investor bought 11,157 shares of the medical research company’s stock, valued at approximately $292,000.
Several other institutional investors also recently bought and sold shares of the company. Cpwm LLC acquired a new position in shares of Accelerate Diagnostics during the 4th quarter worth about $202,000. SeaCrest Wealth Management LLC acquired a new position in shares of Accelerate Diagnostics during the 4th quarter worth about $643,000. Gilder Gagnon Howe & Co. LLC grew its position in shares of Accelerate Diagnostics by 54.9% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 61,420 shares of the medical research company’s stock worth $1,609,000 after buying an additional 21,779 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of Accelerate Diagnostics by 4.3% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 128,814 shares of the medical research company’s stock worth $3,375,000 after buying an additional 5,277 shares during the period. Finally, AXA lifted its holdings in shares of Accelerate Diagnostics by 40.2% during the 3rd quarter. AXA now owns 432,647 shares of the medical research company’s stock valued at $9,713,000 after purchasing an additional 124,035 shares in the last quarter. Institutional investors own 44.86% of the company’s stock.
Several equities analysts have recently weighed in on AXDX shares. BTIG Research cut Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 13th. They noted that the move was a valuation call. Zacks Investment Research upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, January 8th. BidaskClub cut Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. Finally, ValuEngine cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $33.00.
Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings data on Thursday, February 15th. The medical research company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.05. Accelerate Diagnostics had a negative return on equity of 54.66% and a negative net margin of 1,520.99%. The business had revenue of $2.10 million for the quarter. equities analysts expect that Accelerate Diagnostics Inc will post -1.22 EPS for the current year.
In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 15,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The shares were acquired at an average price of $25.15 per share, for a total transaction of $377,250.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jack W. Schuler bought 10,000 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was purchased at an average price of $25.21 per share, for a total transaction of $252,100.00. The disclosure for this purchase can be found here. Insiders have bought a total of 45,100 shares of company stock worth $1,130,850 in the last quarter. 50.00% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This article was posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296023/teacher-retirement-system-of-texas-buys-new-stake-in-accelerate-diagnostics-inc-axdx.html.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc (NASDAQ:AXDX).
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.